usl311

USL311 is an orally bioavailable small molecule antagonist of the C-X-C chemokine receptor type 4 (CXCR4), developed as a potential antineoplastic agent. By binding to CXCR4, USL311 blocks the interaction between CXCR4 and its ligand stromal-cell derived factor 1 (SDF-1 or CXCL12), thereby inhibiting receptor activation. This mechanism may reduce proliferation and migration of tumor cells expressing CXCR4. The drug was primarily investigated for use in advanced solid tumors and relapsed/recurrent glioblastoma multiforme (GBM). Clinical development reached Phase I/II trials but was terminated for business reasons. The compound originated from Ligand Pharmaceuticals and was further developed by Proximagen under Upsher-Smith[1][2][3][4][7].

Other names

2-Pyridinecarboxamide, 6-[hexahydro-4-[1-(1-methylethyl)-4-piperidinyl]-1h-1,4-diazepin-1-yl]-n-4-pyridinyl-UNII-2BTG5MX2Q2UNII2BTG5MX2Q2UNII 2BTG5MX2Q21373268-67-7